Press Releases April 30, 2026 11:00 AM

Monster Beverage to Report Financial Results for 2026 First Quarter on May 7, 2026

Monster Beverage to announce Q1 2026 earnings on May 7 with CEO conference call

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
MNST

Monster Beverage Corporation will report its financial results for the first quarter ended March 31, 2026, on May 7, 2026, after market close. CEO Hilton Schlosberg will host a conference call to discuss the quarter's performance, accessible via webcast for investors and the public.

Monster Beverage to Report Financial Results for 2026 First Quarter on May 7, 2026
MNST
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Monster Beverage Corporation operates in the beverage sector, specializing in energy drinks and flavored malt beverages.
  • The company offers a wide variety of energy drink brands including Monster Energy, Bang Energy, and Reign Total Body Fuel among others.
  • An upcoming investor call aims to review the company's financial results and operations for Q1 2026, providing insights into business performance and strategy.

CORONA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Monster Beverage Corporation (NASDAQ: MNST) announced today that results for its first quarter ended March 31, 2026, will be reported on Thursday, May 7, 2026, after the close of the market. The company also said that Chief Executive Officer, Hilton Schlosberg, will host an investor conference call that same day at 2 p.m. Pacific Time to review the company’s financial results and operations.

The call will be open to all interested investors through a live audio webcast via the Internet at www.monsterbevcorp.com. For those who are not able to listen to the live broadcast, the call will be archived for approximately one year on the website.

Monster Beverage Corporation
Based in Corona, California, Monster Beverage Corporation is a holding company and conducts no operating business except through its consolidated subsidiaries. The Company’s subsidiaries develop and market energy drinks, including Monster Energy® drinks, Monster Energy Ultra® energy drinks, Juice Monster® and Punch Monster® Energy + Juice energy drinks, Java Monster® and Monster Killer Brew® non-carbonated coffee + energy drinks, Rehab® Monster® non-carbonated energy drinks, Monster Energy® Nitro energy drinks, Reign® Total Body Fuel high performance energy drinks, Reign Storm® and StormTM total wellness energy drinks, NOS® energy drinks, Full Throttle® energy drinks, Bang Energy® drinks, FLRT™ total wellness energy drinks, BPM® energy drinks, BU® energy drinks, Burn® energy drinks, Live+® energy drinks, Mother® energy drinks, Nalu® energy drinks, Play® and Power Play® (stylized) energy drinks, Relentless® energy drinks, Samurai® energy drinks, Ultra Energy® drinks, Predator® energy drinks and Fury® energy drinks. The Company’s subsidiaries also develop and market craft beers, flavored malt beverages and hard seltzers under a number of brands, including Jai Alai® IPA, Dale’s Pale Ale®, Dallas Blonde®, Wild Basin® hard seltzers, The Beast®, Beast® Tea, Blind Lemon® and Blinder Lemon™. For more information visit www.monsterbevcorp.com.

CONTACTS:Mark Astrachan SVP, Investor Relations & Corporate Development (951) 739-6200   Roger S. Pondel / Judy Lin PondelWilkinson Inc. (310) 279-5980



Risks

  • Market competition in the energy drink and flavored malt beverage sectors could impact sales and growth.
  • Consumer trends and preferences may shift away from energy drinks or alcoholic beverages, affecting demand.
  • Economic factors and raw material costs could influence profitability and operating results.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026